- Home
- GLAD vs BCYC Comparison
GLAD vs BCYC Comparison
Compare GLAD & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- BCYC
- Stock Information
- Founded
- GLAD 2001
- BCYC 2009
- Country
- GLAD United States
- BCYC United Kingdom
- Employees
- GLAD N/A
- BCYC N/A
- Industry
- GLAD Finance/Investors Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- BCYC Health Care
- Exchange
- GLAD Nasdaq
- BCYC Nasdaq
- Market Cap
- GLAD 612.5M
- BCYC 492.1M
- IPO Year
- GLAD N/A
- BCYC 2019
- Fundamental
- Price
- GLAD $23.57
- BCYC $7.16
- Analyst Decision
- GLAD Hold
- BCYC Buy
- Analyst Count
- GLAD 3
- BCYC 11
- Target Price
- GLAD $24.83
- BCYC $22.91
- AVG Volume (30 Days)
- GLAD 207.4K
- BCYC 220.0K
- Earning Date
- GLAD 11-12-2025
- BCYC 10-30-2025
- Dividend Yield
- GLAD 8.40%
- BCYC N/A
- EPS Growth
- GLAD N/A
- BCYC N/A
- EPS
- GLAD 3.38
- BCYC N/A
- Revenue
- GLAD $88,900,000.00
- BCYC $19,281,000.00
- Revenue This Year
- GLAD N/A
- BCYC N/A
- Revenue Next Year
- GLAD $13.91
- BCYC N/A
- P/E Ratio
- GLAD $6.97
- BCYC N/A
- Revenue Growth
- GLAD N/A
- BCYC N/A
- 52 Week Low
- GLAD $21.96
- BCYC $6.10
- 52 Week High
- GLAD $30.43
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- GLAD 30.47
- BCYC 48.92
- Support Level
- GLAD $22.84
- BCYC $6.77
- Resistance Level
- GLAD $26.29
- BCYC $7.32
- Average True Range (ATR)
- GLAD 0.56
- BCYC 0.39
- MACD
- GLAD -0.17
- BCYC 0.03
- Stochastic Oscillator
- GLAD 19.41
- BCYC 45.91
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.